<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916175</url>
  </required_header>
  <id_info>
    <org_study_id>EN_LC_P134</org_study_id>
    <nct_id>NCT00916175</nct_id>
  </id_info>
  <brief_title>Metabolic Syndrome and Functional Food</brief_title>
  <official_title>Randomized Double Blind Factorial Assay, Aloe Vera (AV) And/Or Cnidoscolus Chayamansa (CC) Versus Placebo, Reduction Of High Blood Glucose In Women With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de Nuevo Leon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autonoma de Nuevo Leon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood sugar and adiposity are part of Metabolic syndrome (about 24% of adults harbor
      it). The main approach, weight reduction, is often unattainable. Aloe Vera (barbadensis) (AV)
      and cnidoscolus chayamansa (McVaugh)(CC) are two vegetables that seem to have an effect on
      blood glucose and body weight.

      The study aims to determine if the intake of aloe gel and/or Chaya infusion can reduce high
      blood sugar in adult women with pre-diabetes (Metabolic Syndrome).

      Methods: A Factorial assay, double blind, cross-over-controlled with random assignment, to
      four treatments: AV and CC, AV and Placebo 1, Placebo 2 and CC, and Placebo 1 and Placebo 2,
      at the outpatient clinic of the university Hospital and a community clinic.

      Two treatment periods of 4 weeks intermediated by one week for wash-out.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of elevated blood sugar (HbA1c) by Immunoturbidimetric test (One-HbA1c FS) via Star-Dust MC15; both from Diagnostic systems international (DiaSys); its coefficient of variation was 1.6%.</measure>
    <time_frame>baseline, and at the end of each of 2 treatment periods of 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant changes on hematic biometry and liver function test and evaluation of any symptoms reported.</measure>
    <time_frame>baseline, and after four weeks of treatment or sooner if needed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance assessed by weekly inquiry of effort needed to take the product, wellbeing, energy, gastrointestinal complains, control of appetite and general complaints.</measure>
    <time_frame>after each week taking the product</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>P1&amp;P2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Food product P1&amp;P2 is composed of: placebo1(mimic aloe vera gel) 30ml and placebo2 (mimic Cnidoscolus chayamansa infusion) 200ml;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P1&amp;CC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food Product P1&amp;CC contains: placebo1 (mimics liquified aloe vera gel) 30ml and Cnidoscolus Chayamansa infusion 200ml;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AG&amp;P2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food product AG&amp;P2 contains (liquified aloe vera gel) 30ml and placebo2 (mimic CC infusion) 200ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AG&amp;CC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food product AG&amp;CC is composed of: liquified aloe vera gel 30ml and Cnidoscolus Chayamansa infusion 200ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TA (concentrated 5:1 aloe vera gel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food product TA contains concentrated 5:1 aloe vera gel by total process30 ml and purified water 200 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Food product Placebo 3 contains stabilizers and preservative used for TA 30 ml and purified water 200 ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>P1&amp;P2</intervention_name>
    <description>First period (4 weeks) intake food product P1&amp;P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet
Second period, cross over from AG&amp;CC group, 4 weeks intake food product P1&amp;P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet</description>
    <arm_group_label>P1&amp;P2</arm_group_label>
    <other_name>Placebo 1 and Placebo 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>P1&amp;CC</intervention_name>
    <description>First period (4 weeks) intake food product P1&amp;CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.
Second period, cross over from AG&amp;P2 group, 4 weeks intake food product P1&amp;CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet.</description>
    <arm_group_label>P1&amp;CC</arm_group_label>
    <other_name>Placebo 1 and Cnidoscolus Chayamansa infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AG&amp;P2</intervention_name>
    <description>First period (4 weeks) intake food product AG&amp;P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.
Second period, cross over from P1&amp;CC group, 4 weeks intake food product AG&amp;P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet</description>
    <arm_group_label>AG&amp;P2</arm_group_label>
    <other_name>Aloe Vera Gel and Placebo 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AG&amp;CC</intervention_name>
    <description>First period (4 weeks) intake food product AG&amp;CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet
Second period, cross over from P1&amp;P2 group, 4 weeks intake food product AG&amp;CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet</description>
    <arm_group_label>AG&amp;CC</arm_group_label>
    <other_name>Aloe Vera gel and Cnidoscolus Chayamansa infusion</other_name>
    <other_name>Sabila &amp; Chaya infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>TA (concentrated 5:1 aloe vera gel)</intervention_name>
    <description>First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.
Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet.</description>
    <arm_group_label>TA (concentrated 5:1 aloe vera gel)</arm_group_label>
    <other_name>Total Aloe concentrated 5:1 aloe vera gel by total process</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>P3</intervention_name>
    <description>First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.
Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet.</description>
    <arm_group_label>P3</arm_group_label>
    <other_name>Placebo 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Adult women living in Monterrey, Mexico with at least three of the following:

               -  waist line equal or larger than 88 cm

               -  fasting blood sugar between 100-140 mg/dL without symptoms or known glucose
                  intolerance or diabetes treated only with diet

               -  known high blood pressure or 2/3 readings systolic &gt; 130 mmHg, diastolic &gt; 85

               -  HLD &lt; 50 mg/dL or triglycerides &gt; 150 mg/dL

        Exclusion Criteria:

          -  Pregnancy or nursing

          -  On anti-diabetic agents

          -  Diabetic symptoms or advanced DM complications

          -  Severe behavioral problems
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilia Cardenas-Ibarra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology, University Hospital, Universidad Autonoma de Nuevo Leon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesus Z Villarreal-Perez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Endocrinology, University Hospital, Universidad Autonoma de Nuevo Leon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fomerrey 19 Community Clinic</name>
      <address>
        <city>Guadalupe</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology, Outpatient clinic of University Hospital UANL</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>54460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>June 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2009</study_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma de Nuevo Leon</investigator_affiliation>
    <investigator_full_name>Lilia Csrdenas-Ibarra</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>hyperglycemia</keyword>
  <keyword>overweight</keyword>
  <keyword>functional food</keyword>
  <keyword>aloe vera</keyword>
  <keyword>cnidoscolus chayamansa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 14, 2017</submitted>
    <returned>April 26, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

